Squarepoint
TRVI icon

Squarepoint’s Trevi Therapeutics TRVI Stock Holding History

Squarepoint’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-103,967
Closed -$1.24M – 4996
2026
Q1 		$1.24M Buy
+103,967
New +$1.16M ﹤0.01% 2591
2025
Q3 		– Sell
-19,149
Closed -$105K – 5017
2025
Q2 		$105K Sell
19,149
-55,403
-74% -$345K ﹤0.01% 4158
2025
Q1 		$469K Buy
74,552
+60,493
+430% +$289K ﹤0.01% 3368
2024
Q4 		$57.9K Buy
+14,059
New +$45K ﹤0.01% 4816
2024
Q2 		– Sell
-15,027
Closed -$51.8K – 4665
2024
Q1 		$51.8K Sell
15,027
-84,464
-85% -$188K ﹤0.01% 3873
2023
Q4 		$133K Buy
+99,491
New +$151K ﹤0.01% 3701
2023
Q2 		– Sell
-11,474
Closed -$21.2K – 4023
2023
Q1 		$21.2K Buy
+11,474
New +$26K ﹤0.01% 3130

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Squarepoint's TRVI Position: Q2 2026 in Review

Squarepoint sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 103,967 shares — an estimated $1.24M sold.

Squarepoint first reported a position in TRVI in Q1 2023 and held it in 7 quarters. The position peaked at $1.24M in Q1 2026. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Squarepoint reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 103,967 Trevi Therapeutics shares in Q2 2026, an estimated $1.24M.
  • Squarepoint first reported a position in Trevi Therapeutics in Q1 2023 and held it in 7 quarters.
  • Squarepoint's Trevi Therapeutics position peaked at $1.24M in Q1 2026.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.